Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAMILIAR trial of imeglimin add-on to DPP-4 inhibitor in type 2 diabetes
jRCTs061210082Completed
- Sponsor
- Sumitomo Pharma
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of imeglimin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sumitomo Pharma. Primary endpoint: Change from baseline in HbA1c at 24 weeks. Started Jul 2022; status: completed.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs061210082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061210082.